We further confirmed this idea by the fact that plasma p-tau181 discriminates AD pathology from non-AD pathology with an AUC of 97.4% 8 years prior to post-mortem, which is of equivalent performance to the well-established CSF AD core biomarkers (Aβ42, p-tau and t-tau) or Aβ and Tau PET. This evidence concerns the gene MAPT and Alzheimer disease.